Aventa Genomics

Aventa Genomics, LLC, a joint venture between Arima Genomics, Inc. and Protean BioDiagnostics, Inc., is a CLIA-certified laboratory dedicated to improving patient outcomes by uncovering druggable targets and resolving diagnostic challenges through the use of 3D genomics tools. Aventa Genomics focuses on sequencing-based tests that detect gene fusions, translocations, and rearrangements. The company examines 361 genes in formalin-fixed paraffin-embedded tumor tissues for gene fusions, translocations, and other rearrangements, enabling physicians to identify druggable targets, understand prognosis, and resolve diagnostic dilemmas.